RNF43-721

N/A

Report date: 2022/10/25 20:00:47

Base Information

Drug NameRNF43-721
Drug Alias NameRNF43-721
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Synthetic peptide vaccine
Mechanisms of ActionE3 ubiquitin-protein ligase RNF43 modulatorsWnt signalling pathway modulatorsImmunostimulants
TargetsE3 ubiquitin-protein ligase RNF43
Therapy Area/IndicationsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTokyo Women'S Medical University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTokyo Women'S Medical UniversityHuman Genome Center, Institute Of Medical Science, University Of Tokyo
Active IndicationsN/A
Inactive IndicationsColorectal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A